Inari Medical, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Year of 2021
January 10, 2022 at 04:01 pm EST
Share
Inari Medical, Inc. provides preliminary unaudited revenue guidance for the fourth quarter and year of 2021. For the quarter, the company expects revenue to be between $82.8 and $83.3 million for the fourth quarter of 2021, up 14% sequentially and 71% year-over-year (at the midpoint of the range).
For the year, the company expects revenue to be between $276.6 and $277.1 million, up approximately 98% over the full year 2020.
Inari Medical, Inc. is a medical device company. The Companyâs products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.
INARI MEDICAL, INC. 
